RxDoctor Payments DataLook up a doctor →

Val Hansen, MD

Internal Medicine · Bountiful, UTNPI 1235224296

Payments from drug & device makers

$67,355in general payments, 2019–2025

Across 272 payments — averaging $247.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$30K
  • AbbVie$17K
  • Takeda Pharmaceuticals U.S.A., Inc.$15K
  • Janssen Research & Development, LLC$2K
  • Astellas Pharma US Inc$311
  • Pfizer$276
  • plus $3K from 39 others
$83,970in research payments, 2019–2025

Across 18 payments — averaging $4664.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$59K
  • Takeda Pharmaceuticals U.S.A., Inc.$14K
  • AbbVie$9K
  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Shire North American Group Inc12$29,879
AbbVie(2 entities)20$17,234
Takeda Pharmaceuticals U.S.A., Inc.16$14,692
Janssen Research & Development, LLC1$2,063
Astellas Pharma US Inc19$311
Pfizer17$276
Novartis19$259
Amgen15$226
Amarin Pharma, Inc.14$216
Lilly USA, LLC12$189
Johnson & Johnson11$184
AstraZeneca13$184
Boehringer Ingelheim10$183
Sanofi-aventis U.S. LLC12$167
Otsuka America Pharmaceutical, Inc.7$129
Bayer7$119
Sumitomo Pharma America, Inc.7$112
GSK7$101
Merck5$74
Novo Nordisk5$67
Mylan Specialty L.p.3$63
Abbott3$62
Biohaven Pharmaceutical Holding Company Ltd.4$58
Idorsia Pharmaceuticals US Inc3$43
Eisai Inc.3$43
Dexcom, Inc.2$32
Nestle Healthcare Nutrition Inc.2$30
Boston Scientific2$30
Amneal Pharmaceuticals LLC2$28
Lucid Diagnostics Inc.2$28
Daiichi Sankyo Inc.2$28
Arbor Pharmaceuticals, Inc.2$26
Actelion Pharmaceuticals US, Inc.1$25
Regeneron Healthcare Solutions, Inc.1$21
Grifols USA, LLC1$21
Bristol Myers Squibb1$19
Tandem Diabetes Care, Inc.1$19
Sanofi Pasteur Inc.1$17
Otsuka Pharmaceutical Development & Commercialization, Inc.1$17
E.r. Squibb & Sons, L.L.C.1$15
Currax Pharmaceuticals LLC1$14
Kowa Pharmaceuticals America, Inc.1$14
Ascensia Diabetes Care US Inc.1$13
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$13
Neurelis, Inc.1$12

How this compares

$67,355 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah →

Medicare billing

Part B allowed, 2024
$36,774
Medicare patients
89
Services billed
504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Bountiful

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →